Ketamine as advanced second‐line treatment in benzodiazepine‐refractory convulsive status epilepticus in children
Epilepsia · 2023-04 · 64 (4) · 797-810
DOI: 10.1111/epi.17550 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Epilepsia, online erschienen am 02.03.2023. Verfasst von Silvia Buratti und 9 weiteren Autor:innen. Beteiligte Einrichtung: Neonatal and Pediatric Intensive Care Unit, Emergency Department, IRCCS Istituto Giannina Gaslini, Genoa, Italy. Hauptthemen laut MEDLINE: Ketamine, Status Epilepticus, Drug Resistant Epilepsy. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Status epilepticus (SE) is one of the most common neurological emergencies in children. To date, there is no definitive evidence to guide treatment of SE refractory to benzodiazepines. The main objectives of treatment protocols are to expedite therapeutic decisions and to use fast‐ and short‐acting medications without significant adverse effects. Protocols differ among institutions, and most frequently valproate, phenytoin, and levetiracetam are used as second‐line treatment. After failure of first‐ and second‐line medications, admission to the intensive care unit and continuous infusion of anesthetics are usually indicated. Ketamine is a noncompetitive N ‐methyl‐D‐aspartate receptor antagonist that has been safely used for the treatment of refractory SE in adults and children. In animal models of SE, ketamine demonstrated antiepileptic and neuroprotective properties and synergistic effects with other antiseizure medications. We reviewed the literature to demonstrate the potential role of ketamine as an advanced second‐line agent in the treatment of SE. Pharmacological targets, pathophysiology of SE, and the receptor trafficking hypothesis are reviewed and presented. The pharmacology of ketamine is outlined with related properties, advantages, and side effects. We summarize the most recent and relevant publications on experimental and clinical studies on ketamine in SE. Key expert opinion is also reported. Considering the current knowledge on SE pathophysiology, early sequential polytherapy should include ketamine for its wide range of positive assets. Future research and clinical trials on SE pharmacotherapy should focus on the role of ketamine as second‐line medication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neonatal and Pediatric Intensive Care Unit, Emergency Department, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
- Intermediate Care Unit, Emergency Department, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
- Emergency Medicine Unit, Emergency Department, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
- Department of Neuroscience (DINOGMI), University of Genoa, Genoa, Italy.
- Pediatric Neurology and Muscular Disease Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
- Child Neuropsychiatry Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
ORCID-Profile: Silvia Buratti, Emanuele Giacheri, Antonella Palmieri, Jessica Tibaldi, Giacomo Brisca, Antonella Riva, Pasquale Striano, Maria Margherita Mancardi, Lino Nobili, Andrea Moscatelli
Zitieren
APA
Buratti, S., Giacheri, E., Palmieri, A., Tibaldi, J., Brisca, G., Riva, A., Striano, P., Mancardi, M. M., Nobili, L., & Moscatelli, A. (2023). Ketamine as advanced second‐line treatment in benzodiazepine‐refractory convulsive status epilepticus in children. Epilepsia, 64(4), 797-810. https://doi.org/10.1111/epi.17550
Vancouver
Buratti S, Giacheri E, Palmieri A, Tibaldi J, Brisca G, Riva A, et al. Ketamine as advanced second‐line treatment in benzodiazepine‐refractory convulsive status epilepticus in children. Epilepsia. 2023;64(4):797-810. doi:10.1111/epi.17550
BibTeX
@article{Buratti2023,
author = {Buratti, Silvia and Giacheri, Emanuele and Palmieri, Antonella and Tibaldi, Jessica and Brisca, Giacomo and Riva, Antonella and Striano, Pasquale and Mancardi, Maria Margherita and Nobili, Lino and Moscatelli, Andrea},
title = {Ketamine as advanced second‐line treatment in benzodiazepine‐refractory convulsive status epilepticus in children},
journal = {Epilepsia},
year = {2023},
volume = {64},
number = {4},
pages = {797--810},
doi = {10.1111/epi.17550}
}
EUVIMED